Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
monarchE: Abemaciclib + Endocrine Therapy in High Risk, Node Positive, Early Stage, HR+, HER2- Breast Cancer
NCT03155997Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 38
01
Overview
A Phase 3 trial of abemaciclib in breast cancer, sponsored by Eli Lilly and Company. Started Jul 2017; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03155997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03155997.